ODI Pharma

The Board of Directors of ODI Pharma AB approved two resolutions for directed issues of shares to increase the company's share capital. The first resolution involves increasing the capital by SEK 70,769.24 through the issuance of 1,769,231 shares at SEK 0.65 per share, with shares allocated to Niclas Kappelin and Volker Wiederrich. The second resolution increases the capital by SEK 25,846.16 through the issuance of 646,154 shares at SEK 1.30 per share, with shares allocated to Derek Simmross and Jan-Mark Edewaard. Both resolutions require approval from shareholders holding at least 90% of votes and shares at the general meeting, as per Chapter 16 of the Swedish Companies Act. ODI Pharma, a company focused on distributing medical cannabis in Europe, aims to become the leading provider in Poland and innovate in medical applications of cannabis products.

Stämman godkände två beslut om riktade nyemissioner av aktier för att öka ODI Pharma AB:s aktiekapital. Den första nyemissionen innebär en ökning med 70 769,24 SEK genom utgivning av 1 769 231 aktier till en teckningskurs av 0,65 SEK per aktie. Investerarna Niclas Kappelin och Volker Wiederrich tilldelas aktier i denna emission. Den andra nyemissionen ökar aktiekapitalet med 25 846,16 SEK genom utgivning av 646 154 aktier till en teckningskurs av 1,30 SEK per aktie, med Derek Simmross och Jan-Mark Edewaard som investerare. Båda besluten kräver godkännande av aktieägare som representerar minst 90 procent av rösterna och de vid stämman företrädda aktierna. ODI Pharma AB fokuserar på produktion och distribution av medicinska cannabisprodukter i Europa, med ambitionen att bli den största leverantören i Polen.

Aktieägare som vill delta i ODI Pharma AB:s bolagsstämma måste vara registrerade i aktieboken hos Euroclear Sweden AB senast den 17 juni 2025 och anmäla sig till bolaget senast den 23 juni 2025. Förvaltarregistrerade aktieägare måste registrera sina aktier i eget namn för att delta. Ombud som representerar aktieägare behöver en skriftlig fullmakt. Vid stämman kommer beslut att tas om riktade nyemissioner av aktier för att öka bolagets kapital. Förslagen innebär att bolagets aktiekapital ökas genom nyemissioner till specifika investerare, däribland styrelsemedlemmar. Dessa emissioner avviker från aktieägarnas företrädesrätt men anses nödvändiga på grund av bolagets akuta kapitalbehov och marknadssituationen. ODI Pharma fokuserar på distribution av medicinsk cannabis i Europa och strävar efter att bli ledande på den polska marknaden.

Shareholders wishing to participate in ODI Pharma AB's General Meeting must be registered with Euroclear Sweden AB by June 17, 2025, and notify the company by June 23, 2025, with their details. Nominee-registered shareholders must ensure their shares are registered in their own name by June 19, 2025. Proxies must bring written authorization and relevant documents to the meeting. The company has 15,915,034 shares and no own shares. The meeting agenda includes opening the meeting, electing a chairman, approving the voting list, certifying the minutes, confirming the meeting's validity, approving the agenda, and discussing the Board's proposals for directed share issues. The Board proposes two directed share issues: one to increase capital by SEK 70,769.24 with 1,769,231 new shares at SEK 0.65 each, and another to increase capital by SEK 25,846.16 with 646,154 new shares at SEK 1.30 each. These issues are aimed at specific investors and require a 90% approval from shareholders. The Board justifies these directed issues due to current market conditions, immediate capital needs, and lower costs compared to a rights issue. Personal data will be used for meeting registration and documentation. Relevant documents and proposals will be available at the company's office and website two weeks before the meeting. Shareholders can request additional information as per Swedish law. ODI Pharma focuses on distributing medical cannabis in Europe, particularly in Poland, with an emphasis on high-quality products and industry partnerships.

The Board of Directors of ODI Pharma has proposed a directed share issue of 2,415,385 new shares to raise approximately SEK 2.0 million. This proposal aims to secure the company's working capital and financial flexibility. The share issue is divided into two parts with different subscription prices and is directed at a limited group of investors, including existing shareholders and board members. The proposal requires approval at an Extraordinary General Meeting (EGM) with a 90% majority due to the involvement of related parties, as stipulated by the Swedish Companies Act. The board opted for this method over a rights issue for its time and cost efficiency and the ability to settle debts with shares. The share issue will increase the company's total shares by 15% and is subject to market conditions. The EGM is scheduled for June 26, 2025, following a notice on June 9, 2025. ODI Pharma focuses on the European medical cannabis market, aiming to be a leading provider in Poland and to innovate in medical cannabis applications.

Under det tredje kvartalet 2025 rapporterade gruppen en nettoomsättning på 2,934,337 SEK, jämfört med 13,856,539 SEK föregående år. Resultatet efter finansiella poster uppgick till -340,612 SEK, jämfört med 1,389,713 SEK tidigare. Resultatet per aktie var -0.02 SEK, jämfört med 0.09 SEK tidigare. För de nio månaderna fram till 31 mars 2025 uppgick nettoomsättningen till 3,064,896 SEK, jämfört med 14,777,194 SEK föregående år. Resultatet efter finansiella poster var -4,153,493 SEK, jämfört med 955,796 SEK tidigare. Resultatet per aktie var -0.26 SEK, jämfört med 0.06 SEK tidigare. Soliditeten var 11%, jämfört med 23% föregående år. Under andra kvartalet meddelade ODI Pharma att de avslutar sitt avtal med Pareto Securities AB. Inga betydande händelser inträffade efter periodens slut. ODI Pharma är en producent och distributör av farmaceutiska cannabisprodukter med fokus på den europeiska marknaden, särskilt i Polen. Företaget strävar efter att erbjuda högkvalitativa produkter till konkurrenskraftiga priser och att leda utvecklingen av medicinska applikationer för cannabis.

During the second quarter of 2024, ODI Pharma reported no net sales, a significant drop from SEK 1,175 in the previous year. The group's loss after financial items was SEK -2,562,520, compared to a profit of SEK 946,531 previously. The result per share was SEK -0.16, down from SEK 0.06. Over the six months from July to December 2024, net sales were SEK -4,965, down from SEK 780,209, and the loss after financial items was SEK -3,953,290, compared to a previous loss of SEK -491,846. The result per share was SEK -0.25, down from SEK -0.03, and solidity was 7%, down from 28%. Key events included a decision by ODI's Board on October 30, 2024, to issue new shares with preferential rights for existing shareholders, subject to approval at an upcoming Extraordinary General Meeting. The rights issue aims to raise approximately SEK 4.1 million, with potential additional funds through oversubscription. Malcolm Allan was proposed as a new board member, and Jan-Mark Edewaard was announced as the new CEO starting January 1, 2025, succeeding Derek Simmross. ODI also provided updates on Poland's medical cannabis market, where it holds a strong position. The rights issue was subscribed to 54.8%, raising around SEK 2.2 million. Derek Simmross did not participate in the rights issue, reducing his shareholding below 25%. After the reporting period, ODI announced the termination of its liquidity provider agreement with Pareto Securities AB, effective March 14, 2025. ODI Pharma focuses on distributing medical cannabis in Europe, particularly in Poland, aiming to be a leading provider by offering competitive, high-quality products.